Recruiting

Testing a new treatment for pustules on hands and feet

Plain-English translation of NCT07219420 on ClinicalTrials.gov ↗ · Source last updated May 2026 · Translation generated June 2026 · How we translate trials

Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.

What is this trial?

This study is testing a medication called to see if it can help people with palmoplantar pustulosis—a painful skin condition that causes clusters of pustules (small fluid-filled bumps) on the palms of the hands and/or soles of the feet. About 320 people will participate, and some will receive the medication while others will receive a placebo (a dummy treatment) at first. The goal is to understand whether this treatment works better than placebo and is safe to use.

Palmoplantar pustulosis is a difficult-to-treat skin condition that significantly impacts quality of life, and current treatment options are limited. Researchers are testing this medication because early evidence suggests it may help control the pustules and improve symptoms.

Do you qualify?

You likely qualify if…

you are at least 18 years old
you have been diagnosed with palmoplantar pustulosis for at least 6 months
you have active pustules on your palms and/or soles of your feet (with at least 5 pustules and moderate severity)
your skin condition is severe enough that you are a candidate for systemic therapy or phototherapy
you have moderate to severe disease based on clinical scoring at screening and baseline visits

You likely don't qualify if…

your symptoms have improved significantly between screening and the start of treatment
you have other types of psoriasis (such as plaque psoriasis, generalized pustular psoriasis, or erythrodermic psoriasis) or other skin conditions like eczema
your skin condition was caused by or worsened by certain medications (such as beta blockers, lithium, or TNF inhibitors)
you are currently taking or have previously taken other IL-17 inhibitor medications, including bimekizumab
you have skin lesions that would interfere with evaluating your palmoplantar pustulosis

What participation looks like

If you enroll, you will be randomly assigned to receive either the medication or a placebo during the initial phase of the study. Those who start with placebo will switch to receiving the medication in the later maintenance phase. You will have regular visits to a clinic where your skin will be examined and assessed, and researchers will monitor you for any side effects. The study includes an initial treatment period followed by an extended period where participants continue on the medication.

AI-generated summary from trial data · Jun 2, 2026 · Not medical advice

Trial locations(41 sites)

Canada

Ppp001 50233, Barrie

Ppp001 50749, Fredericton

Ppp001 50765, London

Ppp001 50740, Québec

Ppp001 50752, Red Deer